162 related articles for article (PubMed ID: 30333913)
1. Synthetic lethality of the ALDH3A1 inhibitor dyclonine and xCT inhibitors in glutathione deficiency-resistant cancer cells.
Okazaki S; Shintani S; Hirata Y; Suina K; Semba T; Yamasaki J; Umene K; Ishikawa M; Saya H; Nagano O
Oncotarget; 2018 Sep; 9(73):33832-33843. PubMed ID: 30333913
[TBL] [Abstract][Full Text] [Related]
2. Vasodilator oxyfedrine inhibits aldehyde metabolism and thereby sensitizes cancer cells to xCT-targeted therapy.
Otsuki Y; Yamasaki J; Suina K; Okazaki S; Koike N; Saya H; Nagano O
Cancer Sci; 2020 Jan; 111(1):127-136. PubMed ID: 31692172
[TBL] [Abstract][Full Text] [Related]
3. Glutaminolysis-related genes determine sensitivity to xCT-targeted therapy in head and neck squamous cell carcinoma.
Okazaki S; Umene K; Yamasaki J; Suina K; Otsuki Y; Yoshikawa M; Minami Y; Masuko T; Kawaguchi S; Nakayama H; Banno K; Aoki D; Saya H; Nagano O
Cancer Sci; 2019 Nov; 110(11):3453-3463. PubMed ID: 31444923
[TBL] [Abstract][Full Text] [Related]
4. xCT inhibitor sulfasalazine depletes paclitaxel-resistant tumor cells through ferroptosis in uterine serous carcinoma.
Sugiyama A; Ohta T; Obata M; Takahashi K; Seino M; Nagase S
Oncol Lett; 2020 Sep; 20(3):2689-2700. PubMed ID: 32782585
[TBL] [Abstract][Full Text] [Related]
5. CISD2 inhibition overcomes resistance to sulfasalazine-induced ferroptotic cell death in head and neck cancer.
Kim EH; Shin D; Lee J; Jung AR; Roh JL
Cancer Lett; 2018 Sep; 432():180-190. PubMed ID: 29928961
[TBL] [Abstract][Full Text] [Related]
6. Targeting aldehyde dehydrogenase activity in head and neck squamous cell carcinoma with a novel small molecule inhibitor.
Kim J; Shin JH; Chen CH; Cruz L; Farnebo L; Yang J; Borges P; Kang G; Mochly-Rosen D; Sunwoo JB
Oncotarget; 2017 Aug; 8(32):52345-52356. PubMed ID: 28881734
[TBL] [Abstract][Full Text] [Related]
7. Induction of ferroptotic cell death for overcoming cisplatin resistance of head and neck cancer.
Roh JL; Kim EH; Jang HJ; Park JY; Shin D
Cancer Lett; 2016 Oct; 381(1):96-103. PubMed ID: 27477897
[TBL] [Abstract][Full Text] [Related]
8. Mechanism of Cell Death by Combined Treatment with an xCT Inhibitor and Paclitaxel: An Alternative Therapeutic Strategy for Patients with Ovarian Clear Cell Carcinoma.
Idei U; Ohta T; Yamatani H; Seino M; Nagase S
Int J Mol Sci; 2023 Jul; 24(14):. PubMed ID: 37511540
[TBL] [Abstract][Full Text] [Related]
9. Temozolomide toxicity operates in a xCT/SLC7a11 dependent manner and is fostered by ferroptosis.
Sehm T; Rauh M; Wiendieck K; Buchfelder M; Eyüpoglu IY; Savaskan NE
Oncotarget; 2016 Nov; 7(46):74630-74647. PubMed ID: 27612422
[TBL] [Abstract][Full Text] [Related]
10. The role of system Xc
Dang DK; Shin EJ; Tran HQ; Kim DJ; Jeong JH; Jang CG; Nah SY; Sato H; Nabeshima T; Yoneda Y; Kim HC
Neurochem Int; 2017 Sep; 108():254-265. PubMed ID: 28457879
[TBL] [Abstract][Full Text] [Related]
11. Kinetic analysis of cystine uptake and inhibition pattern of sulfasalazine in A549 cells.
Okamoto K; Saito Y; Ueda H; Narumi K; Furugen A; Kobayashi M
Biopharm Drug Dispos; 2021 Sep; 42(8):389-392. PubMed ID: 34287957
[TBL] [Abstract][Full Text] [Related]
12. Functional interactions of the cystine/glutamate antiporter, CD44v and MUC1-C oncoprotein in triple-negative breast cancer cells.
Hasegawa M; Takahashi H; Rajabi H; Alam M; Suzuki Y; Yin L; Tagde A; Maeda T; Hiraki M; Sukhatme VP; Kufe D
Oncotarget; 2016 Mar; 7(11):11756-69. PubMed ID: 26930718
[TBL] [Abstract][Full Text] [Related]
13. The Styryl Benzoic Acid Derivative DC10 Potentiates Radiotherapy by Targeting the xCT-Glutathione Axis.
Sarowar S; Cirillo D; Játiva P; Nilsen MH; Otragane SA; Heggdal J; Selheim F; Ceña V; Bjørsvik HR; Enger PØ
Front Oncol; 2022; 12():786739. PubMed ID: 35198439
[TBL] [Abstract][Full Text] [Related]
14. Impact of the glutathione synthesis pathway on sulfasalazine-treated endometrial cancer.
Sendo K; Seino M; Ohta T; Nagase S
Oncotarget; 2022; 13():224-236. PubMed ID: 35106124
[TBL] [Abstract][Full Text] [Related]
15. xCT inhibition depletes CD44v-expressing tumor cells that are resistant to EGFR-targeted therapy in head and neck squamous cell carcinoma.
Yoshikawa M; Tsuchihashi K; Ishimoto T; Yae T; Motohara T; Sugihara E; Onishi N; Masuko T; Yoshizawa K; Kawashiri S; Mukai M; Asoda S; Kawana H; Nakagawa T; Saya H; Nagano O
Cancer Res; 2013 Mar; 73(6):1855-66. PubMed ID: 23319806
[TBL] [Abstract][Full Text] [Related]
16. Dose-escalation study for the targeting of CD44v
Shitara K; Doi T; Nagano O; Imamura CK; Ozeki T; Ishii Y; Tsuchihashi K; Takahashi S; Nakajima TE; Hironaka S; Fukutani M; Hasegawa H; Nomura S; Sato A; Einaga Y; Kuwata T; Saya H; Ohtsu A
Gastric Cancer; 2017 Mar; 20(2):341-349. PubMed ID: 27055559
[TBL] [Abstract][Full Text] [Related]
17. Interleukin-6 facilitates tumor progression by inducing ferroptosis resistance in head and neck squamous cell carcinoma.
Li M; Jin S; Zhang Z; Ma H; Yang X
Cancer Lett; 2022 Feb; 527():28-40. PubMed ID: 34902522
[TBL] [Abstract][Full Text] [Related]
18. Sulfasalazine, an inhibitor of the cystine-glutamate antiporter, reduces DNA damage repair and enhances radiosensitivity in murine B16F10 melanoma.
Nagane M; Kanai E; Shibata Y; Shimizu T; Yoshioka C; Maruo T; Yamashita T
PLoS One; 2018; 13(4):e0195151. PubMed ID: 29649284
[TBL] [Abstract][Full Text] [Related]
19. Aldehyde dehydrogenases and cell proliferation.
Muzio G; Maggiora M; Paiuzzi E; Oraldi M; Canuto RA
Free Radic Biol Med; 2012 Feb; 52(4):735-46. PubMed ID: 22206977
[TBL] [Abstract][Full Text] [Related]
20. Mitochondrial dysfunction enhances cisplatin resistance in human gastric cancer cells via the ROS-activated GCN2-eIF2α-ATF4-xCT pathway.
Wang SF; Chen MS; Chou YC; Ueng YF; Yin PH; Yeh TS; Lee HC
Oncotarget; 2016 Nov; 7(45):74132-74151. PubMed ID: 27708226
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
